EP1278519A4 - Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor - Google Patents

Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor

Info

Publication number
EP1278519A4
EP1278519A4 EP01928470A EP01928470A EP1278519A4 EP 1278519 A4 EP1278519 A4 EP 1278519A4 EP 01928470 A EP01928470 A EP 01928470A EP 01928470 A EP01928470 A EP 01928470A EP 1278519 A4 EP1278519 A4 EP 1278519A4
Authority
EP
European Patent Office
Prior art keywords
neoplasia
topoisomerase
inhibitor
patient
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01928470A
Other languages
German (de)
French (fr)
Other versions
EP1278519A2 (en
Inventor
Rifat Pamukcu
Joseph Lobacki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Publication of EP1278519A2 publication Critical patent/EP1278519A2/en
Publication of EP1278519A4 publication Critical patent/EP1278519A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01928470A 2000-04-12 2001-04-12 Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor Withdrawn EP1278519A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54813500A 2000-04-12 2000-04-12
US548135 2000-04-12
PCT/US2001/011865 WO2001078651A2 (en) 2000-04-12 2001-04-12 Method for treating neoplasmin with topoisomase i inhibitor

Publications (2)

Publication Number Publication Date
EP1278519A2 EP1278519A2 (en) 2003-01-29
EP1278519A4 true EP1278519A4 (en) 2003-05-07

Family

ID=24187563

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01928470A Withdrawn EP1278519A4 (en) 2000-04-12 2001-04-12 Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor

Country Status (3)

Country Link
EP (1) EP1278519A4 (en)
AU (1) AU2001255322A1 (en)
WO (1) WO2001078651A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275228A1 (en) * 2000-06-06 2001-12-17 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
WO1997047303A1 (en) * 1996-06-13 1997-12-18 Cell Pathways, Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754864B2 (en) * 1998-03-28 2002-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona, The DFMO and sulindac combination in cancer chemoprevention
US6200771B1 (en) * 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
WO1997047303A1 (en) * 1996-06-13 1997-12-18 Cell Pathways, Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUFFY, C. P. ET AL: "Enhancement of chemotherapeutic drug toxicity to human tumor cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)", EUROPEAN JOURNAL OF CANCER (1998), 34(8), 1250-1259, XP002198488 *

Also Published As

Publication number Publication date
EP1278519A2 (en) 2003-01-29
WO2001078651A2 (en) 2001-10-25
WO2001078651A3 (en) 2002-03-14
AU2001255322A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
EP1131069A4 (en) Method for treating a patient with neoplasia by treatment with a platinum coordination complex
EP1353676A4 (en) Method for treating fibrotic diseases or other indications
HK1086829A1 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for treating pain
AU2002210293A1 (en) Continuous water cycle water treatment apparatus
AU2002215125A1 (en) Well treatment method
HK1053129A1 (en) A method for treating allergies
GB0008624D0 (en) Dermatological treatment apparatus
GB0129976D0 (en) Treatment method
ZA200502307B (en) Method for treating patients with massive blood loss
EP1294411A4 (en) A novel treatment for cough
EP1128727A4 (en) Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
PL362462A1 (en) Apparatus for lipolysis for aesthetic treatment
AU751887B2 (en) Guide bar including stump treatment
AU9716001A (en) Guide bar including stump treatment
GB0120147D0 (en) Treatment method
EP1278519A4 (en) Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor
IL155769A0 (en) Method for the treatment of inflammation
EP1260486A4 (en) Method for treating organic wastewater
AU2001238609A1 (en) Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
SG89379A1 (en) Treatment apparatus
GB0026838D0 (en) Treatment method
EP1355645A4 (en) Method for treating fibrotic diseases or other indications iiic
EP1267911A4 (en) A method of treatment
IL145799A0 (en) Method for treating neurodegeneration
HK1039872A2 (en) A wastewater treatment method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021108

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030325

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 45/06 B

Ipc: 7A 61K 31/4745 B

Ipc: 7A 61K 31/192 A

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSI PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20070419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070830